T4	Concept 243 263	SARS-CoV-2 infection
T5	Concept 267 271	lung
T6	Concept 220 239	antiviral treatment
T2	Concept 203 219	better potential
R2	has-property Arg1:T6 Arg2:T2	
R3	in-context Arg1:T6 Arg2:T4	
R5	in-place Arg1:T4 Arg2:T5	
T8	Concept 305 310	CD147
T10	Concept 357 367	SARS-CoV-2
T3	Action 296 304	blocking
R4	target Arg1:T3 Arg2:T8	
T7	Concept 318 328	host cells
R7	in-place Arg1:T8 Arg2:T7	
T11	Concept 336 353	inhibitory effect
R6	causes Arg1:T3 Arg2:T11	
R8	in-context Arg1:T11 Arg2:T10	
T9	Concept 401 406	CD147
T13	Concept 447 457	host cells
T15	Concept 486 496	SARS-CoV-2
T16	Concept 512 526	urinary system
T17	Action 501 507	invade
R9	subject Arg1:T17 Arg2:T15	
R10	target Arg1:T17 Arg2:T16	
T18	Concept 528 548	hematological system
T19	Concept 553 569	digestive system
R11	target Arg1:T17 Arg2:T18	
R12	target Arg1:T17 Arg2:T19	
T20	Concept 585 603	respiratory system
R13	target Arg1:T17 Arg2:T20	
T21	Concept 630 638	symptoms
R14	has-property Arg1:T17 Arg2:T21	
A1	Uncertain T21
T22	Concept 679 690	salt-bridge
T23	Concept 672 678	strong
T25	Concept 709 713	R426
T26	Concept 717 729	SARS-CoV RBD
T27	Concept 734 738	E329
T28	Concept 742 746	ACE2
T29	Concept 788 802	SARS-CoV-2 RBD
T30	Action 751 758	missing
R16	target Arg1:T30 Arg2:T29	
R18	has-property Arg1:T22 Arg2:T23	
R19	has-part Arg1:T26 Arg2:T25	
R20	has-part Arg1:T28 Arg2:T27	
R15	in-context Arg1:T22 Arg2:T26	
R17	in-context Arg1:T22 Arg2:T28	
R21	subject Arg1:T30 Arg2:T22	
T24	Concept 871 879	COVID-19
T31	Concept 890 909	coronavirus disease
R22	is-a Arg1:T24 Arg2:T31	
T32	Concept 844 853	ritonavir
T33	Concept 858 867	lopinavir
T34	Concept 822 840	therapeutic effect
R23	in-context Arg1:T34 Arg2:T24	
R24	has-property Arg1:T32 Arg2:T34	
R25	has-property Arg1:T33 Arg2:T34	
T35	Action 924 927	due
R26	subject Arg1:T35 Arg2:T24	
T36	Concept 937 954	inhibitory effect
R27	target Arg1:T35 Arg2:T36	
T37	Concept 958 965	CEP_C30
R28	in-place Arg1:T36 Arg2:T37	
T38	Concept 973 982	ritonavir
T39	Concept 1001 1009	efficacy
T40	Concept 992 1000	stronger
T41	Action 987 991	have
R29	subject Arg1:T41 Arg2:T38	
R30	target Arg1:T41 Arg2:T39	
R31	has-property Arg1:T39 Arg2:T40	
T42	Concept 1049 1059	SARS-CoV-2
T43	Concept 1068 1096	potential therapeutic effect
T45	Concept 1122 1139	inhibitory effect
T46	Concept 1143 1147	PLVP
R33	in-context Arg1:T45 Arg2:T46	
T44	Concept 1015 1045	inhibitory effect of darunavir
R35	in-context Arg1:T44 Arg2:T42	
R32	has-property Arg1:T44 Arg2:T43	
R36	causes Arg1:T44 Arg2:T45	
R34	subject Arg1:T35 Arg2:T31	
T47	Action 410 422	facilitating
R37	subject Arg1:T47 Arg2:T9	
T12	Concept 423 442	SARS-CoV-2 invasion
R38	target Arg1:T47 Arg2:T12	
R39	in-place Arg1:T12 Arg2:T13	
T49	Concept 47 54	tissues
T50	Concept 69 73	lung
R1	in-place Arg1:T49 Arg2:T50	
T51	Action 122 131	indicated
T52	Concept 143 176	pharmacokinetic profile of CVL218
T14	Concept 134 142	superior
R44	has-property Arg1:T52 Arg2:T14	
R45	target Arg1:T51 Arg2:T52	
T53	Concept 37 43	CVL218
R46	is-a Arg1:T53 Arg2:T6	
T1	Concept 13 33	higher distributions
R40	has-property Arg1:T53 Arg2:T1	
R41	in-context Arg1:T53 Arg2:T49	
R42	subject Arg1:T51 Arg2:T53	
